ArticleBMC infectious diseases2026
Molecular epidemiology and genetic characteristics of enterovirus A identified in pediatric patients with hand, foot, and mouth disease and herpangina in Linyi, China, 2023-2024, following the relaxation of COVID-19 policies.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThe molecular characteristics of enterovirus (EV) circulating in Linyi remain unclear following the relaxation of COVID-19 control policies in December 2022. This study aims to clarify the EV spectrum and genetic features in Linyi during 2023–2024, providing a reference for future surveillance and prevention of EV infections.
methodsPediatric patients with suspected EV infection were enrolled, and throat swabs were collected. RT-qPCR was used to detect EV, and positive samples were further typed by semi-nested PCR. The genomes of each EV-A serotype were amplified and sequenced for molecular characteristic analysis. Phylogenetic trees were constructed based on the VP1 gene, whole genome, P1, P2, and P3 regions using the Neighbor-Joining method. Recombination events among the strains identified in Linyi were analyzed using RDP4 and SimPlot.
resultsAmong 806 suspected cases of enterovirus infection, 565 (70.1%) were positive. Of these positive cases, 427 (75.6%) were identified as EV-A. Five EV-A serotypes were identified, including coxsackievirus A4 (CVA4), A5 (CVA5), A6 (CVA6), A10 (CVA10), and A16 (CVA16). The predominant serotype shifted from CVA6 in 2023 to CVA4 and CVA16 in 2024. The CVA4, CVA5, CVA6, and CVA10 strains identified in Linyi belonged to genotypes (subgenotypes or clades) C2, D, D3a, and C2, respectively. The CVA16 strains identified in Linyi were assigned to clades B1b and B1c. Additionally, a local recombination event between CVA5 and CVA6 was identified.
conclusionsAfter the relaxation of COVID-19 control policies, multiple EV-A serotypes, including CVA4, CVA5, CVA6, CVA10, and CVA16, have been circulating in Linyi. The B1c clade of CVA16 was identified in Shandong Province for the first time. A local recombination event was detected among some strains in Linyi. The epidemiology of EV in Linyi has changed, and it is necessary to monitor these strains for their potential to cause outbreaks or severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.